Fat loss

Body weight, belly fat, appetite and blood sugar. Ranked by evidence grade, then user score. Each grade is for the use named on the card, which may not be this goal.

• Sleep
• Recovery & injury
• Fat loss
• Cognition & mood
• Libido & sexual health
• Longevity
• Skin & hair
• Immune
• Muscle & strength

Evidence grade Any grade A only B or better C or better D or better US FDA Any status Approved for this useApproved for another use onlyNot approved WADA (sport) Any status Not prohibitedProhibited or likely prohibitedNot named / unclear

12 of 12 peptides shown

1. A

   1.Semaglutide

   Strong human evidence · for weight management and type 2 diabetes

   FDA Approved WADA Not prohibited
   User score 4.0
   Outcomes: Positive 17 of 24 (71%), Mixed 6 of 24 (25%), Unclear 2 of 24 (8%)
   Men 45–60: 9 · everyone: 24 reports · approximate

   Why it’s listed: graded use mentions it; substance class mentions it; summary mentions it; 20 of 24 user reports mention fat loss; 7 of 24 user reports mention appetite reduction.

2. A

   2.Tirzepatide

   Strong human evidence · for weight management and type 2 diabetes

   FDA Approved WADA Not prohibited
   User score 4.0
   Outcomes: Positive 17 of 23 (74%), Mixed 5 of 23 (22%), Negative 1 of 23 (4%)
   Men 45–60: 8 · everyone: 23 reports · approximate

   Why it’s listed: graded use mentions it; substance class mentions it; summary mentions it; 18 of 23 user reports mention fat loss; 8 of 23 user reports mention appetite reduction.

3. B

   3.Retatrutide

   Moderate human evidence · for weight loss

   FDA Not approved WADA Likely prohibited (S0)
   User score 3.0
   Outcomes: Positive 12 of 25 (48%), Mixed 7 of 25 (28%), Negative 3 of 25 (12%), Unclear 3 of 25 (12%)
   Men 45–60: 5 · everyone: 25 reports · approximate

   Why it’s listed: graded use mentions it; substance class mentions it; page tags mentions it; summary mentions it; 15 of 25 user reports mention fat loss.

4. B

   4.Tesamorelin

   Moderate human evidence · for visceral / abdominal fat reduction in people without HIV

   FDA Approved for HIV-related belly fat only WADA Prohibited (S2.2.4)
   User score 2.5
   Outcomes: Positive 10 of 23 (43%), Mixed 4 of 23 (17%), Negative 6 of 23 (26%), No effect 1 of 23 (4%), Unclear 2 of 23 (9%)
   Men 45–60: 2 · everyone: 23 reports · approximate

   Why it’s listed: graded use mentions it; page tags mentions it; 9 of 23 user reports mention fat loss.

5. C

   5.Ipamorelin

   Preliminary human data · for raising growth hormone for sleep and body composition

   FDA Not approved WADA Prohibited (S2.2.4)
   User score 4.0
   Outcomes: Positive 34 of 48 (71%), Mixed 8 of 48 (17%), Negative 4 of 48 (8%), No effect 2 of 48 (4%)
   Men 45–60: 2 · everyone: 48 reports · approximate

   Why it’s listed: 15 of 48 user reports mention fat loss.

6. C

   6.CJC-1295

   Preliminary human data · for raising growth hormone for body composition, recovery and sleep

   FDA Not approved WADA Prohibited (S2.2.4)
   User score 2.5
   Outcomes: Positive 6 of 12 (50%), Mixed 1 of 12 (8%), Negative 2 of 12 (17%), Unclear 3 of 12 (25%)
   Men 45–60: 1 · everyone: 12 reports · approximate

   Why it’s listed: 3 of 12 user reports mention fat loss.

7. C

   7.Sermorelin

   Preliminary human data · for adult growth-hormone 'optimisation', sleep and body composition

   FDA Approval withdrawn WADA Prohibited (S2.2.4)
   User score 2.0
   Outcomes: Positive 16 of 48 (33%), Mixed 10 of 48 (21%), Negative 16 of 48 (33%), No effect 3 of 48 (6%), Unclear 3 of 48 (6%)
   Men 45–60: 1 · everyone: 48 reports · approximate

   Why it’s listed: 13 of 48 user reports mention fat loss.

8. D

   8.5-Amino-1MQ

   Preclinical only · for fat loss and metabolism

   FDA Not approved WADA Likely prohibited (S0)
   User score 2.5
   Outcomes: Positive 10 of 22 (45%), Mixed 3 of 22 (14%), Negative 3 of 22 (14%), Unclear 6 of 22 (27%)
   Men 45–60: 0 · everyone: 22 reports · approximate

   Why it’s listed: graded use mentions it; page tags mentions it; 8 of 22 user reports mention fat loss.

9. D

   9.Human growth hormone fragment 176–191

   Preclinical only · for fat loss (native-sequence hGH 176-191)

   FDA Not approved WADA Prohibited (S2.2.3)
   User score 2.5
   Outcomes: Positive 7 of 19 (37%), Mixed 5 of 19 (26%), Negative 1 of 19 (5%), No effect 2 of 19 (11%), Unclear 4 of 19 (21%)
   Men 45–60: 0 · everyone: 19 reports · approximate

   Why it’s listed: graded use mentions it; page tags mentions it; 11 of 19 user reports mention fat loss.

10. D

    10.MOTS-c

    Preclinical only · for metabolism, exercise performance and longevity

    FDA Not approved WADA Prohibited (S4.4.1)
    User score 2.5
    Outcomes: Positive 10 of 25 (40%), Mixed 7 of 25 (28%), Negative 4 of 25 (16%), No effect 3 of 25 (12%), Unclear 2 of 25 (8%)
    Men 45–60: 2 · everyone: 25 reports · approximate

    Why it’s listed: graded use mentions it.

11. D

    11.IGF-1 LR3

    Preclinical only · for muscle growth and recovery

    FDA Not approved WADA Prohibited (S2.3)
    User scoretoo few reports (6)
    Men 45–60: 0 · everyone: 6 reports · approximate

    Why it’s listed: 2 of 6 user reports mention fat loss.

12. F

    12.AOD-9604

    Tested and failed · for fat loss

    FDA Not approved WADA Prohibited (S2.2.3)
    User scoretoo few reports (6)
    Men 45–60: 0 · everyone: 6 reports · approximate

    Why it’s listed: graded use mentions it; page tags mentions it.

User reports are anecdata, not evidence: self-selected, unverified, often combined with other compounds.